Newly Expanded Incyte Ingenuity Award Program Issues Call for Submissions

An initiative of global biopharmaceutical company Incyte, the Incyte Ingenuity Award program supports the graft-versus-host disease (GVHD) community by funding two novel initiatives that address a challenge faced by GVHD patients, caregivers, and healthcare providers.

GVHD is a life-threatening condition that occurs when donor immune cells attack the recipient's organs and tissues after an allogeneic stem cell transplant. There are two major forms of GVHD, acute and chronic, that can affect multiple organ systems, including the skin, digestive tract, and the liver. Both acute and chronic GVHD are associated with significant morbidity and mortality.

Incyte is deeply dedicated to improving the lives of patients with serious diseases, including GVHD. As a part of that commitment, the company is re-opening the program application period to continue to foster collaboration among key stakeholders aimed at addressing the specific needs of the GVHD community.

Following feedback received from the GHVD community after the award program's inaugural year in 2020, the program is being expanded to include a $35,000 award for smaller-scale projects, in addition to the original $100,000 award.

The program is open to nonprofit 501(c)(3), patient, policy, and caregiver organizations; healthcare providers and mid-level/junior faculty at healthcare organizations; and individuals or companies collaborating with such organizations and institutions.

Programs must be independent of any ongoing activities, with the exception of significant expansions of an existing program. programs cannot include indirect costs with the proposed budget.

Applications will be disqualified if the focus of the proposed program is a particular therapeutic agent, translational research, or clinical research that is interventional in nature; the organization is improperly identified as a 501(c)(3) organization; the application is submitted by a healthcare professional as an individual; the defined scope of the program does not serve or plan to address a specific need of the GVHD community; the request in funding exceeds 25 percent of an organization’s overall funding and/or includes indirect costs; the program exceeds the maximum application limit per organization (more than five); and/or the program is based on an existing initiative, with no evidence of ingenuity.

To be eligible, applicants and their host organization must be based in the U.S. (including Washington DC and Puerto Rico).

For more information, see the Incyte Ingenuity Awards website.

View another RFP related to medical research

Deadline: May 14, 2021